Zevra Reports Second Quarter 2026 Financial Results and Corporate Update
Stocks in this Quantisnow insightHealth Care
Historical context for ZVRA
Across the 29 sessions after earlier ZVRA headlines, the stock closed higher 14 times and lower 15 times, with a median move of 2.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ZVRA | SPY |
|---|---|---|---|
| Aug 4, 2026 | Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference | +4.6% | +1.8% |
| Aug 3, 2026 | Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC) | +5.7% | +1.4% |
| Jul 24, 2026 | Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union | -23.9% | +0.1% |
| Jul 22, 2026 | Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call | -2.5% | -0.1% |
| Jun 23, 2026 | Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC) | +2.8% | -1.5% |
| Jun 11, 2026 | Zevra's Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition | -3.9% | +1.7% |
Quantisnow market dataNASDAQ
ZVRA
Zevra Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for ZVRA
Full ZVRA profile on Quantisnow Follow ZVRA and get a push notification the moment its next story breaks.